key: cord-0926837-3ivdw9o9 authors: Businaro, Pietro; Vaghi, Gloria; Marchioni, Enrico; Diamanti, Luca; Arceri, Sebastiano; Bini, Paola; Colombo, Elena; Cosentino, Giuseppe; Alfonsi, Enrico; Costa, Alfredo; Ravaglia, Sabrina; Mallucci, Giulia; Ballante, Elena; Franciotta, Diego; Gastaldi, Matteo title: COVID‐19 in patients with myasthenia gravis: Epidemiology and disease course date: 2021-06-12 journal: Muscle Nerve DOI: 10.1002/mus.27324 sha: 3b001532c7e665b35e6509fbb36541ffef8cd2f8 doc_id: 926837 cord_uid: 3ivdw9o9 INTRODUCTION/AIMS: Coronavirus disease 2019 (COVID‐19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection, has become a global pandemic. Patients with myasthenia gravis (MG), often treated with immunosuppressants, might be at higher risk of developing COVID‐19 and of demonstrating a severe disease course. We aimed to study prevalence and describe features of COVID‐19 in MG patients. METHODS: In May 2020, we conducted telephonic interviews with MG patients followed at our referral center. We collected structured data regarding MG and COVID‐19, which was diagnosed as probable or confirmed according to the European Centre for Disease Prevention and Control case definition. We compared confirmed‐COVID‐19 prevalence calculated from the beginning of the pandemic in MG patients with that of the overall Pavia district. RESULTS: We interviewed 162 MG patients (median age, 66 y; interquartile range 41‐77; males 59.9%), 88 from the Pavia district. Three patients had SARS‐CoV‐2‐confirmed by polymerase chain reaction and eight had probable‐COVID‐19. In the Pavia district, the prevalence of confirmed‐COVID‐19 among MG patients (1/88, 1.14%) and overall population (4777/546 515, 0.87%) did not differ (P = .538). Higher Myasthenia Gravis Foundation of America clinicalclass and the need for recent rescue treatment, but not ongoing immunosuppressive treatments, were associated with COVID‐19 risk. Of 11 MG patients with probable/confirmed‐COVID‐19, 3 required ventilator support, and 2 elderly patients died of COVID‐19 respiratory insufficiency. Only 1 of11 patients experienced worsening MG symptoms, which improved after increasing their steroid dose. DISCUSSION: The risk of COVID‐19 in MG patients seems to be no higher than that of the general population, regardless of immunosuppressive therapies. In our cohort, COVID‐19 barely affected MG course. In the past year coronavirus disease 2019 (COVID-19), a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, has rapidly spread to become a worldwide pandemic. 1 Therapeutic management is particularly challenging due to the lack of specific antiviral treatment and is mainly based on supportive care. Italy and in particular the Lombardy region, was one of the most affected areas in Europe during the first wave of COVID-19 in early 2020. It is uncertain whether patients with myasthenia gravis (MG), an autoimmune disorder affecting the neuromuscular junction (NMJ), might be at higher risk of developing COVID-19, for example, due to the immunosuppressive treatment often received. 2 Moreover, these patients might face a particularly severe COVID-19 course since infections can trigger MG exacerbations, and some treatments administered in COVID-19, such as hydroxychloroquine, might further worsen MG manifestations. [3] [4] [5] [6] Management of MG patients during the SARS-CoV-2 pandemic has been guided by expert consensus, but data on COVID-19-MG patients are still lacking. 7 We aimed to study COVID-19 infection risk and disease course in MG patients followed at our Institution, located in an area severely affected by the pandemic (the Pavia district in Lombardy), during the first COVID-19 wave in Italy. We screened our electronic records for patients with a diagnosis of suspected MG with at least one outpatient visit at our Institution in the past 3 years, identifying 264 patients ( Figure 1 ). A total of 102 patients were excluded from the study ( Figure 1 Numerical variables are described as median and quartiles, categorical variables as percentage or row count. Categorical variables were analyzed using Fisher's exact test or Pearson's chi-squared test, while numerical data using Mann-Whitney test. COVID-19 prevalence in the overall population were obtained from the SARS-CoV-2-integrated-surveillance system of the "Istituto Superiore di Sanità" F I G U R E 1 Algorithm of the study. Data regarding the Pavia province population were obtained from the national institute of statistics. 8 Data regarding the Pavia province COVID-19 prevalence were obtained from the SARS-CoV-2 surveillance system 9 ( Figure 1 ). 9,12 COVID-19 prevalence in MG patients was calculated from February 1 and was reported with 95% confidence intervals (CIs). 8 Our hospital is the main referral center for MG in the Pavia district; thus, we considered our cohort as representative of the MG population in this area. Prevalence estimated in MG patients was compared with that of the overall population using the exact binomial test. P values <.05 were considered significant. The study was approved by the local ethics committee. Overall, 162 patients completed the telephonic interview. Eleven had symptoms suggestive of COVID-19, and 6 underwent nasopharyngeal swab testing with SARS-CoV-2 real-time PCR. Three patients were positive and diagnosed with "confirmed-COVID-19." The remaining eight patients were classified as "probable-COVID-19" based on compatible symptoms and close contact with an infected subject in the weeks preceding symptoms onset. In the Pavia district, the estimate prevalence of "confirmed-COVID-19" was 1.14% (95% CI: 0.02%-6.17%) in our MG patients, and 0.87% (95% CI: 0.85%-0.90%) in the overall population, according to surveillance systems of the Italian Ministry of Health (Figure 1 ) 8,12 without difference in disease prevalence between the two cohorts (P = .538). The clinical features of the 162 MG patients are summarized in Currently, no epidemiological studies on COVID-19 in MG patients are available, and data regarding SARS-CoV-2 infection risk in this population are scarce. Studies on patients with other autoimmune diseases suggest that immunosuppressive therapy does not represent a risk factor for SARS-CoV-2 infection and that some drugs might even be protective. 13, 14 Indeed steroids, the most common medication for MG patients in our cohort, are effective in reducing the mortality in COVID-19. 15 In our study, we found that COVID-19 prevalence did not differ between MG patients and the general population in the Pavia district. Interestingly, among the whole cohort of MG patients, the type of treatment received did not influence the occurrence of COVID-19, supporting the safety of MG treatments in the current pandemic. We found that MG patients with oncologic/autoimmune comorbidity were more likely to develop COVID-19, suggesting that SARS- been suggested for other conditions, such as systemic autoimmune diseases. 13 However, it should also be considered that this particular subset of fragile patients might have been monitored and tested more carefully than the other MG patients. In most patients, MG remains stable throughout the SARS-CoV-2 infection, but some of them experience worsening of MG symptoms. 2, 5 In such cases, additional treatment, such as intravenous immunoglobulins or steroids, might be effective and should be considered early on to prevent severe complications. 7 In our study, the treatments received were not clearly related to the final outcome, that was overall favorable. Only two elderly patients died, possibly reflecting the high mortality rate found in COVID-19 in this age range. 16 Our study has limitations. First of all, it is possible that some MG patients residing in the Pavia district could not be followed at our Insti- In conclusion, in accordance with consensus guidelines, our data suggest that patients with MG should continue their immunosuppressive therapy in the current pandemic, even in cases of clinically overt COVID-19. In most patients in our cohort, the infection did not dramatically influence the MG course, but larger studies are needed to clarify the course of COVID-19 in MG patients. We thank the following Colleagues for providing patients' information: Alfredo Romani, Giovanni Piccolo, Maria Lombardi, Mauro Ceroni. This study was sponsored by the Italian Ministry of Health "Ricerca Corrente" to the IRCCS Mondino Foundation (grant code: RC20011C). None of the authors has any conflict of interest to disclose. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. https://orcid.org/0000-0002-5990-4640 Sabrina Ravaglia https://orcid.org/0000-0001-8749-3706 Clinical characteristics of coronavirus disease 2019 in China Management of patients with generalised myasthenia gravis and COVID-19: four case reports Myasthenia gravis and infectious disease COVID-19 in patients with myasthenia gravis Description of 3 patients with myasthenia gravis and COVID-19 Myasthenic syndrome caused by hydroxychloroquine used for COVID-19 prophylaxis Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic Diagnosis and treatment of myasthenia gravis SARS-CoV-2 infection among patients with systemic autoimmune diseases An Italian programme for COVID-19 infection in multiple sclerosis Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19. A meta-analysis Age-specific SARS-CoV-2 infection fatality ratio and associated risk factors, Italy COVID-19 in patients with myasthenia gravis: Epidemiology and disease course